Kalorama Information: Roche Diagnostics, Abbott, Siemens and Danaher's Beckman Coulter Continue to Dominate IVD

ROCKVILLE, Md., Oct. 5, 2016 /PRNewswire/ -- Roche is still the leader of the 60 billion-dollar in vitro diagnostics market and no competitor comes close, according to research firm Kalorama Information, followed by Abbott, Siemens, and Danaher-owned Beckman Coulter.  The healthcare market research firm focuses on in vitro diagnostic and biotech markets, and completes a biennial report on the market place.   Still, that's no reason not to keep watching companies, Kalorama says, as there's a fair amount of movement in the remainder of the market.  The market share finding was made in the tenth edition of its The Worldwide Market for In Vitro Diagnostic Test, published in August.  The firm also computes a complete market share and ranks 18 other companies according to estimated 2016 revenues. The report is available at http://www.kaloramainformation.com/Worldwide-Vitro-Diagnostic-10206771/

"Although this doesn't reflect a change from previous reporting, we see the possibility of change on the second, third and fourth market share positions," said Bruce Carlson, Publisher of Kalorama Information.  "The leadership places come from high-dollar chemistry and legacy immunoassay systems.  As focus moves away from these, a change there in the next few years would not be surprising."

Collectively the four largest IVD companies earn 46% of the revenue in the IVD market, according to Kalorama Information's report.  But the report doesn't think this limits opportunity for the scores of mid-size competitors and hundreds of small companies that participate in clinical testing instruments, chemicals and supplies.

"There is still plenty of opportunity, thirty-two billion dollars, for the rest of the market and new entrants as the growth opportunity will be different in different market segments," said Bruce Carlson, Publisher of Kalorama Information. "None of the majors, including Roche, grow at the rate as they did eight a few editions ago.  There's a constant need to innovate and part of that means partnering or purchasing with dynamic upstarts."

Roche Diagnostics continues to dominate the industry with 2016 revenues twice that of its nearest competitors.  Roche's growth is linked to its molecular (PCR) IP, chemistries, immunoassays, HPV testing and diabetes franchise.  The company has reinforced its molecular and sequencing offerings, has branched out into prenatal analysis, genomics and cfDNA for cancer testing.  The company purchase of Constitution Medical Investors, Bloodhound digital hematology and subsequent introduction of its cobas m 511 integrated hematology analyzer is a potential game changer in hematology.  Similar to its development of the Bloodhound platform for hematology testing, Kalorama thinks Roche's acquisition of GeneWeave can be interpreted as a move to introduce itself into an IVD segment where it has not maintained a consistent or significant presence. 

Abbott Diagnostics holds the second spot.  Its core focus area of infectious disease testing increased double digits operational basis last year.   The company is preparing for the future with the development of next generation systems, informatics to help labs manage and retrieve test data, new infectious disease diagnostics and gene-based oncology tests for targeted therapeutics.  For example in 2014 and 2015, Abbott acquired Omnilab (Sydney, Australia), expanding lab informatics capabilities, announced a collaboration with Sekisui to offer coagulation testing solutions, launched i-STAT Total ß-hCG blood test, allowing faster detection of early pregnancy in emergency situations, announced European regulatory approval for the Iridica system for microbiology and launched ARCHITECT Clinical Chemistry Hemoglobin A1c test.

Siemens Healthineers has initiated the Agenda 13 plan to stimulate product development.  Launched in November 2011, Agenda 2013 is a two-year global initiative to strengthen the innovative power and competitiveness of the Siemens Healthcare Sector.  Agenda 2013 includes a program to improve the cost position in the Diagnostics Division.  Also part of the plan was a rebranding exercise that changed the company's name from Siemens Healthcare Diagnostics to Siemens Healthineers.

Siemens is downsizing to concentrate on core lab and molecular diagnostics. July 2014, Beckman Coulter agreed to acquire Siemens Healthcare Diagnostics' Microscan microbiology product line that includes the MicroScan Instruments and MicroScan panels/consumables, along with data management solutions.  Siemens had acquired Microscan as part of the Dade Behring business in 2007.  

Beckman Coulter was acquired by Danaher Corporation in February 2011.  Geographically, Beckman Coulter's diagnostics sales were generated 22% in Europe, 50% in North America and 12% in Asia.  In 2015, Danaher reported that the company's diagnostic's business, meanwhile, grew at mid-single digits, with Beckman Coulter's core diagnostic sales growing at a low single-digit rate based on strong immunoassay and urinalysis product sales.   Beckman Coulter has taken action to bolster its lagging IVD revenues with the acquisition of Siemens' microbiology and alliances such as that with Ortho Clinical Diagnostics.  June 2016, Beckman Coulter and Ortho Clinical Diagnostics announced a partnership whereby Beckman Coulter will place Ortho's VITROS 3600 System running HIV and hepatitis assays in labs that currently run Beckman's Power Processor Sample Handling Systems, automation solution, and in certain very high-volume laboratories.      

In addition to these companies, the report says Thermo Fisher, Alere, Biomerieux, Sysmex, Hologic and Bio-Rad are competitive in the IVD market. 

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.  

Press Contact:
Bruce Carlson
212 807 2262     
[email protected]  

Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO

SOURCE Kalorama Information